17种植物中蛋白质提取物的抗HIV-1活性

以化合物对ＨＩＶ１诱导Ｃ８１６６细胞形成合胞体的抑制实验和化合物对ＨＩＶ１感染细胞的保护实验作为初筛方法，筛选了来源于７科１７种植物的４７个样品，其中８个样品经测定是核糖体失活蛋白（ＲＩＰｓ），其余为粗提蛋白。进而测定了初筛有抗ＨＩＶ活性的化合物对共培养、急性和慢性感染的ＨＩＶ１ｐ２４抗原表达水平的影响，用间接荧光染色检测这些化合物对ＨＩＶ抗原阳性细胞率的影响，以确证其抗ＨＩＶ活性。天花粉蛋白（ＴＣＳ）、南方栝楼蛋白峰Ⅴ、南方栝楼蛋白峰Ⅵ均显著地抑制合胞体的形成；巴Ⅱ、丝瓜子蛋白、油瓜根蛋白、木盍藤子蛋白有一定的抑制作用。老鼠拖瓜蛋白、大叶木鳖子根蛋白、西双版纳根Ⅱ等粗提蛋白有显著的抑制作用。ＲＩＰｓ不能保护ＨＩＶ１感染细胞的死亡。ＴＣＳ显著地抑制了ＨＩＶ１急性感染中ｐ２４抗原的表达，减少了ＨＩＶ抗原阳性细胞数，但它们均不影响共培养细胞融合、ＨＩＶ１慢性感染中ｐ２４抗原表达水平。结果表明，除ＴＣＳ等已知ＲＩＰｓ外，还有一些新的ＲＩＰｓ具有不同程度的抗ＨＩＶ活性。

卵叶槲寄生化学成分体外抗HIV活性的初步研究

　目的: 探讨卵叶槲寄生化学成分的体外抗人免疫缺陷病毒(H IV)活性。方法:采用四甲基偶氮唑蓝法测定化合物的细胞毒性;细胞病变法检测化合物对H IV急性感染的抑制活性; H IV21 p24抗原EL ISA方法检测化合物对慢性感染细胞中H IV复制的影响。计算化合物的抑制率和半数抑制浓度(EC50 )。结果:多种卵叶槲寄生的化学成分具有体外抑制H IV复制的作用,特别是3, 5, 7, 4′2 四羟基23′2 甲氧基黄烷酮和圣草酚。3,5, 7, 4′2 四羟基23′2 甲氧基黄烷酮在2～3μg·mL- 1的浓度范围内对H IV21和H IV22复制的抑制率均≥50%,而对 C8166细胞的半数细胞毒性浓度(CC50 ) >200μg·mL - 1。圣草酚在低浓度(1. 5～2. 5μg·mL- 1 )时,对H IV21和H IV22复制的抑制率达50%,其对C8166细胞的CC50为43. 40μg·mL - 1。结论:卵叶槲寄生化学成分3, 5, 7, 4′2四羟基23′2 甲氧基黄烷酮和圣草酚对H IV21和H IV22的体外复制均有不同程度的抑制作用。

HIV-1慢性感染Jurkat细胞系的建立及其特性研究

目的　建立艾滋病病毒Ⅰ型( HIV21) 慢性感染J urkat 细胞系,研究其生物学特性。方法　参照文献方法改良,建立HIV21 ⅢB慢性感染J urkat 细胞系。其细胞系特性采用以下方法检测:光学显微镜观察细胞形态;流式细胞仪检测HIV21 ⅢB感染细胞的阳性率;噻唑蓝(MTT) 法检测抗病毒药物对慢性感染细胞的毒性作用;酶联免疫吸附试验( EL ISA) 检测药物对慢性感染细胞中病毒复制的影响;合胞体形成方法检测药物对HIV21 ⅢB慢性感染细胞与正常细胞融合的阻断作用。结果　成功建立了HIV21 慢性感染J urkat 细胞系(J urkat/ HIV21 ⅢB ) ,感染细胞阳性率> 90 %。检测影响病毒复制各周期的抗病毒药物对J urkat/ HIV21 ⅢB细胞的作用,发现J urkat/ HIV21 ⅢB细胞具有 HIV21 慢性感染细胞的生物学特征。结论　成功建立J urkat/ HIV21 ⅢB 细胞系,为抗HIV21 药物的研发和病毒感染机制研究提供了新的工具。

云南省HIV-1分子流行病学研究进展

云南省是中国HIV-1感染最早和最为严重的地区之一,流行的HIV-1病毒亚型种类复杂多样。已有证据表明国内其它地区的HIV-1亚型很可能主要来源于云南省。本文对云南省的HIV-1亚型的流行情况进行综述,希望能为预防控制云南省乃至全国HIV-1的流行以及合理设计HIV-1疫苗提供基础信息。

三个非核苷类逆转录酶抑制剂S-DABO类衍生物的体外抗HIV作用(英文)

本文对3个新S-DABO类衍合物(RZK-4、RZK-5、RZK-6)的体外抗HIV活性进行了研究。化合物RZK-4、RZK-5和RZK-6在200μg·mL-1的浓度下均能完全抑制HIV-1逆转录酶的活性。3个化合物对多种细胞均呈现出低毒性,且均在较低浓度下具有抑制HIV-1病毒实验株、临床株和耐药株的作用,治疗指数为3704～38462。其中,化合物RZK-6对HIV-1耐药株HIV-1IIIBA17具有非常显著的抑制作用。结果表明,这3种S-DABO类衍生物有良好的体外抗HIV-1作用,具有开发成为抗HIV-1药物的前景。

我国中药来源的抗HIV天然化合物研究进展

由于迄今仍无艾滋病(acquired immunodeficiency syndrome,AIDS)疫苗问世,抗人类免疫缺陷病毒(human immunodeficiency virus,HIV)药物仍然是艾滋病治疗的主要手段。传统中药和药用植物来源的天然化合物具有结构多样性、毒性较低、来源广泛等特点,因而在防治艾滋病方面有着独特的优势和巨大的潜力。研究者已经对天然化合物抗HIV作用进行了大量研究,并取得了可喜的成绩,发现了一些生物碱、香豆素、木脂素、黄酮类、萜类、鞣质类、多糖类、蛋白质和多肽类等天然化合物具有抗HIV的活性。然而,多数研究都是在体外试验完成的,大多数天然化合物体外抗HIV活性偏低,而且抗HIV的靶点仍不十分清楚。本文结合笔者实验室研究工作,重点介绍近年来我国传统中药来源的抗HIV活性较强的天然化合物研究进展。

HIV感染中的细胞凋亡

HIV感染以后,病毒蛋白的持续性产出导致免疫系统的持续性激活,引起Th1细胞的丢失,Th1细胞通过合成Ⅰ型细胞因子,抑制淋巴细胞的自发凋亡。另外,病毒蛋白或其他因素能够使CD4~(+)、CD8~(+) T细胞和APC转化为凋亡的效应细胞,通过Fas/FasL或其他途径引起细胞凋亡。HIV感染人体后凋亡细胞不仅有CD4~(+) T细胞,还包括B细胞、NK细胞、粒细胞、神经细胞和单细胞。凋亡作为机体的自我防护措施,在清除感染细胞的同时,并没有抑制HIV在单细胞/巨噬细胞内的复制,反而造成大量未感染细胞的凋亡,导致对HIV复制的失控,发展为严重的免疫缺陷,引起AIDS相关的机会性感染。

半乳糖神经酰胺脂质体对HIV-1感染性的影响

目的研究体外空白及包封抗HIV药物和PFA的GalCer脂质体对HIV-1复制的影响。方法通过HIV p24抗原测定、合胞体抑制实验、融合阻断实验和对HIV感染细胞的保护作用实验等，观察了空白GalCer脂质体、AZT-GalCer脂质体和PFA-GalCer脂质体对HIV-1复制的影响。结果空白GalCer脂质体预处理细胞，能促进HIV-1感染CD4＋细胞；空白GalCer脂质体预处理HIV-1，则抑制了病毒吸附和结合宿主细胞；GalCer脂质体还具有阻断HIV-1感染细胞与正常CD4＋细胞间的融合作用；GalCer脂质体包封AZT或PFA不能显著提高药物体外抗HIV-1活性。结论空白GalCer脂质体预处理细胞，能促进HIV-1感染性；预处理HIV-1，则抑制了病毒的感染。

非核苷类逆转录酶抑制剂在抗HIV-1中的作用

非核苷类RT抑制剂是一大类化学结构各异的化合物,它们结合于RT上一个非底物结合的变构部位,使RT失去活性。从天然化合物中寻找新的非核苷类RT抑制剂是一条治疗HIV-1感染的极有希望的途径。

Anti-HIV-1 activity of trichobitacin, a novel ribosome-inactivating protein

AIM: To determine whether trichobitacin, a novel ribosome-inactivating protein purified from the root tubers of Trichosanthes kirilowii, possesses the anti-HIV activity. METHODS: The inhibition of syncytial cell formation induced by human immunodeficiency virus type 1 (HIV-1),was determined under microscope, reduction of HIV-1 p24 antigen expression level was measured by ELISA, and decrease in numbers of HIV-1 antigen positive cells in acutely and-chronically infected cultures were detected by indirect immunofluorescence assay. RESULTS: Trichobitacin Was-found to greatly suppress syncytial cell formation induced by HIV-1 and to markedly reduce both expression of HIV-1 p24 antigen and the number of HIV antigen positive cells in acutely but not chronically HIV-1 infected culture. The median inhibitory concentration (IC50) in inhibition of syncytial cell formation and HIV antigen positive cells were 5 mu g.L-1 (95 % confidence limits: 1.3 - 20 mu g.L-1) and 0.09 mg.L-1 (95 % confidence limits: 0.011 - 0.755 mg.L-1), respectively. CONCLUSION: Trichobitacin is a novel ribosome-inactivating protein with anti-HIV-l activity.

Anti-HIV-1 property of trichosanthin correlates with its ribosome inactivating activity

Trichosanthin (TCS) is a type I ribosome inactivating (RI) protein possessing anti-tumor and antiviral activity, including human immunodeficiency virus (HIV). The mechanism of these actions is not entirely clear, but is generally attributed to its RI property. In order to study the relationship between the anti-HIV-1 activity of TCS and its RI activity, three TCS mutants with different RI activities were constructed by using site-directed mutagenesis. The anti-HIV-1 activities of the three mutants were tested in vitro. Results showed that two TCS mutants, namely TCSM((120-123)), TCSE160A/E189A, with the greatest decrease in RI activity, lost almost all of the anti-HIV activity and cytopathic effect. Another mutant TCSR122G, which exhibited a 160-fold decrease in RI activity, retained some anti-HIV activity. The results from this study suggested that RI activity of TCS may have significant contribution to its anti-HIV-1 property. (C) 2002 Published by Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies.

Independency of anti-HIV-1 activity from ribosome-inactivating activity of trichosanthin

Trichosanthin (TCS) is a type I ribosome-inactivating (RI) protein possessing multiple biological and pharmacological activities. Its major action is inhibition of human immunodeficiency virus (HIV) replication but the mechanism is still elusive. All evidences showed that this action is related to its RI activity. Previous studies found that TCS mutants with reduced RI activity simultaneously lost some anti-HIV activity. In this study, an exception was demonstrated by two TCS mutants retaining almost all RI activity but were devoid of anti-HIV-1 activity. Five mutants were constructed by using site-directed mutagenesis with either deletion or addition of amino acids to the C-terminal sequence. Results showed that the RI activity of mutants with C-terminal deletion mutants (TCSC2, TCSC4, and TCSC14) decreased by 1.2-3.3-fold with parallel downshifting of its anti-HIV-1 activity (1.4-4.8-fold). Another two mutants, TCSC19aa and TCSKDEL having 19 amino acid extension and a KDEL signal sequence added to the C-terminal sequence, retained all RI activity but subsequently lost most of the anti-HIV-1 activity. These findings suggested that ribosome inactivation alone might not be adequate to explain the anti-HIV action of TCS. (C) 2003 Elsevier Science (USA). All rights reserved.

Xanthohumol, a novel anti-HIV-1 agent purified from Hops Humulus lupulus

Xanthohumol, prenylchacone flavonoid, is a natural product with multi-biofunctions purified from Hops Humulus lupulus. Its anti-HIV-1 activity was tested in the present study. Results showed that xanthohumol inhibited HIV-1 induced cytopathic effects, the production of viral p24 antigen and reverse transcriptase in C8166 lymphocytes at non-cytotoxic concentration. The EC50 values were 0.82, 1.28 and 0.50 mug/ml, respectively. The therapeutic index (TI) was about 10.8. Xanthohumol also inhibited HIV-1 replication in PBMC with EC50 value of 20.74 mug/ml. The activity of recombinant HIV-1 reverse transcriptase and the HIV-1 entry were not inhibited by xanthohumol. The results from this study suggested that xanthohumol is effective against HIV-1 and might serve as an interesting lead compound. It may represent a novel chemotherapeutic agent for HIV-1 infection. However, the mechanism of its anti-HIV-1 effect needs to be further clarified. (C) 2004 Elsevier B.V. All rights reserved.

Zinc coupling potentiates anti-HIV-1 activity of baicalin

Baicalin (BA) has been shown with anti-HIV-1 activity. Zinc is a nutrient element. The anti-HIV-1 activity of zinc complex of baicalin (BA-Zn) in vitro was studied and compared with the anti-HIV-1 activities between BA and BA-Zn in the present study. Our results suggested that BA-Zn has lower cytotoxicity and higher anti-HIV-1 activity compared with those of BA in vitro. The CC(50)s of BA-Zn and BA were 221.52 and 101.73 muM, respectively. The cytotoxicity of BA-Zn was about 1.2-fold lower than that of BA. The BA and BA-Zn inhibited HIV-1 induced syncytium formation, HIV-1 p24 antigen and HIV-1 RT production. The EC(50)s of BA-Zn on inhibiting HIV-1 induced syncytium formation (29.08 muM) and RT production (31.17 muM) were lower than those of BA (43.27 and 47.34 muM, respectively). BA-Zn was more effective than BA in inhibiting the activities of recombinant RT and HIV-1 entry into host cells. Zinc coupling enhanced the anti-HTV-1 activity of baicalin. (C) 2004 Elsevier Inc. All rights reserved.

Site-directed PEGylation of trichosanthin retained its anti-HIV activity with reduced potency in vitro

Trichosanthin (TCS) was the first ribosome inactivating protein found to possess anti-HIV-1 activity. Phase I/II clinical trial of this compound had been done. Antigenicity and short plasma half-life were the major side effects preventing further clinical trial. Modification of TCS is therefore necessary to revive the interest to develop this compound as an anti-HIV agent. Three potential antigenic sites (Ser-7, Lys-173, and Gln-219) were identified by computer modeling. Through site-directed mutagenesis, these three antigenic amino acids were mutated to a cysteine residue resulting in 3 TCS mutants, namely S7C, K173C, and Q219C. These mutants were further coupled to polyethylene glycol with a molecular size of 20 kDa (PEG) via the cysteine residue. This produced another three TCS derivatives, namely PEG(20)k-S7C, PEG(20)k-K173C, and PEG(20)k-Q219C. PEGylation had been widely used recently to decrease immunogenicity by masking the antigenic sites and prolong plasma half-life by expanding the molecular size. The in vitro anti-HIV-1 activity of these mutants and derivatives was tested. Results showed that the anti-HIV-1 activity of S7C, K173C, and Q219C was decreased by about 1.5- to 5.5-fold with slightly lower cytotoxicity. On the other hand, PEGylation produced larger decrease (20- to 30-fold) in anti-HIV activity. Cytotoxicity was, however, weakened only slightly by about 3-fold. The in vitro study showed that the anti-HIV activity of PEGylated TCS was retained with reduced potency. The in vivo activity is expected to have only slightly changed due to other beneficial effects like prolonged half-life. (C) 2004 Elsevier Inc. All rights reserved.